ReShape Lifesciences宣布战略性裁员;发布与Vyome Therapeutics的合并协议以及与Biorad Medisys的资产购买协议的最新消息

Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses

Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025

IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced strategic headcount reduction and provided an update on the merger agreement with Vyome Therapeutics and asset purchase agreement with Biorad Medisys.